Skip to content
Publicly Available Published by De Gruyter December 2, 2021

Blood lactate concentration in COVID-19: a systematic literature review

  • Giovanni Carpenè , Diletta Onorato , Riccardo Nocini , Gianmarco Fortunato , John G. Rizk ORCID logo , Brandon M. Henry and Giuseppe Lippi ORCID logo EMAIL logo

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious respiratory condition sustained by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which manifests prevalently as mild to moderate respiratory tract infection. Nevertheless, in a number of cases the clinical course may deteriorate, with onset of end organ injury, systemic dysfunction, thrombosis and ischemia. Given the clinical picture, baseline assessment and serial monitoring of blood lactate concentration may be conceivably useful in COVID-19. We hence performed a systematic literature review to explore the possible association between increased blood lactate levels, disease severity and mortality in COVID-19 patients, including comparison of lactate values between COVID-19 and non-COVID-19 patients. We carried out an electronic search in Medline and Scopus, using the keywords “COVID-19” OR “SARS-CoV-2” AND “lactate” OR “lactic acid” OR “hyperlactatemia”, between 2019 and present time (i.e. October 10, 2021), which allowed to identify 19 studies, totalling 6,459 patients. Overall, we found that COVID-19 patients with worse outcome tend to display higher lactate values than those with better outcome, although most COVID-19 patients in the studies included in our analysis did not have sustained baseline hyperlactatemia. Substantially elevated lactate values were neither consistently present in all COVID-19 patients who developed unfavourable clinical outcomes. These findings suggest that blood lactate monitoring upon admission and throughout hospitalization may be useful for early identification of higher risk of unfavourable COVID-19 illness progression, though therapeutic decisions based on using conventional hyperlactatemia cut-off values (i.e., 2.0 mmol/L) upon first evaluation may be inappropriate in patients with SARS-CoV-2 infection.

Introduction

Coronavirus disease 2019 (COVID-19), a new life-threatening infectious pathology caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is generating dramatic clinical impacts worldwide, with substantial derangements in the organization of healthcare, society and economy. From a clinical perspective, COVID-19 is mainly characterized by lower respiratory tract infection, which, in some patients, may evolve into acute respiratory distress syndrome (ARDS), multiple organ failure (MOF), and even death [1].

Hyperlactatemia is traditionally associated with poor outcomes in critically ill patients [2], and lactate value is regarded as one of the most important biomarkers of illness severity in patients with sepsis [3]. Although COVID-19 is a predominantly pulmonary disorder, it is also associated with end organ injury, systemic dysfunction, thrombosis, and ischemia [4], so that baseline assessment and serial monitoring of blood lactate concentration may be at least theoretically useful in this clinical setting. Nonetheless, the association between blood lactate values and clinical outcome remains unclear in patients with SARS-CoV-2 infection. Here we report the results of a systematic review aimed at exploring the possible association between increased blood lactate levels, disease severity and mortality in COVID-19 patients, including a comparison of lactate values between COVID-19 and non-COVID-19 patients.

Methods

We carried out an electronic search in Medline (PubMed interface) and Scopus, using the keywords “COVID-19” OR “SARS-CoV-2” AND “lactate” OR “lactic acid” OR “hyperlactatemia”, between 2019 and present time (i.e. October 10, 2021), restricted to articles published in English. The reference list of all documents was also reviewed for identifying other potentially eligible documents. All resulting items were screened (title, abstract and full text, when available or necessary) by two of the authors (GC and GL), in order to capture observational, cross-sectional or prospective studies reporting data on lactate values at admission (or at the earliest time point during hospitalization) in COVID-19 patients with or without severe disease, as well as in non-survivors vs. survivors. Severe disease was clinically defined as patients needing intensive care unit (ICU) admission, mechanical ventilation, hospitalization, pneumonia or onset of critical symptoms (ARDS) and/or shock and/or presence of organ failure. All studies fulfilling this criteria were then included in a systematic literature review. Disagreements between authors with respect to study eligibility were resolved by discussion and consensus. Results of the review were organized into summary of findings tables.

Results

Studies identification and characteristics

A total number of 2,659 studies were initially identified by our search criteria, 1,112 of which were excluded for duplication among the two databases, whilst 1,528 were also excluded because they failed to report lactate values. Nineteen studies, totalling 6,459 patients, were finally included in our systematic review [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23]. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram is shown in Figure 1, whist the PRISMA checklist is available as Supplementary File 1. The characteristics of the included studies are reported in Tables 14. All reported blood lactate values were measured upon hospital admission or at the earliest time point immediately after hospitalization (i.e., within 24 h). Velavan et al. [10] measured blood lactate concentrations not only in hospitalized patients but also in COVID-19 outpatients in home quarantine. Two studies by Hokenek et al. [6] and Kalabin et al. [16] reported both severity and mortality as clinical endpoints in their cohorts.

Figure 1: 
Preferred reporting items for systematic reviews and meta-analyses (PRISMA) diagram.
Figure 1:

Preferred reporting items for systematic reviews and meta-analyses (PRISMA) diagram.

Evidence on COVID-19 disease severity

In the study of Hokenek et al. [6], patients were classified according to their lactate concentration. The cut-off value was set at blood lactate concentration >2 mmol/L, and patients with elevated levels were found to have a higher rate of ICU admission (Table 1). Four additional studies (totalling 436 patients, 114 of whom (26.1%) with severe disease) compared blood lactate values in severe vs. non-severe cases [10, 16, 18, 19]. Velavan et al. [10], Kalabin et al. [16], and Chen et al. [18] found that patients with severe disease had higher blood lactate values compared to non-severe patients. Unlike these findings, Yang et al. [19] reported that patients with severe disease did not display higher blood lactate values compared to those with non-severe illness (Table 2).

Table 1:

Clinical outcome in coronavirus disease 2019 (COVID-19) patients with or without hyperlactatemia.

Study ID Country Type of study Sample size Sex, M/F Age, years, mean Outcomes Baseline lactate <2 mmol/L Baseline lactate >2 mmol/L p-Value endpoint
Total patients Severe patients Non-severe patients Total patients Severe patients Non-severe patients
Bruno et al. [5] Europe Prospective 2,860 2034/826 ≥70 Mortality 1,940 817 (43%) 1,123 (57%) 920 465 (53%) 455 (47%) <0.001
Hokenek and Rohat [6] Turkey Retrospective 292 158/134 68 ± 16 Mortality 156 44 (28%) 112 (72%) 136 57 (42%) 79 (58%) 0.02
Hokenek and Rohat [6] Turkey Retrospective 292 158/134 68 ± 16 ICU admission 156 25 (16%) 131 (84%) 136 38 (28%) 98 (72%) 0.02
  1. ICU, intensive care unit.

Table 2:

Lactate levels in coronavirus disease 2019 (COVID-19) patients with or without severe illness.

Study ID Country Type of study Sample size Sex, M/F Age, years, mean Lactate value (mmol/L) (mean) p-Value Endpoint
Non-severe patients Severe patients
Velavan et al. [10] Germany NR 34 19/15 18–83 1.28 2.97 0.002 Hospitalization
Kalabin et al. [16] USA Retrospective 184 111/73 65 ± 15 2.14 ± 2.01 3.27 ± 2.61 0.34 Mechanical ventilation
Chen et al. [18] China Retrospective 148 90/58 58 (48–64) 1.7 (1.4–1.9) 3.3 (2.3–4.4) NR Critical symptomsa
Yang et al. [19] China Case series 70 38/32 45 (34–61) 2.03 (1.50–2.95) 1.89 (1.61–3.45) 0.040 Patients with pneumonia
  1. NR, not reported. aCritical symptoms: ARDS (PaO2/FiO≤100 mmHg) and requiring mechanical ventilation and/or shock occurs and/or presence of organ failure.

Evidence on COVID-19 mortality

In two of the studies which described the risk of death in patients with blood hyperlactatemia (cut-off value set at blood lactate concentration >2 mmol/L) [5, 6], the risk of death was found to be higher in COVID-19 patients with elevated blood lactate values (Table 1). Eleven additional studies compared blood lactate values in COVID-19 survivors vs. non-survivors (2,744 total patients, 671 (24.5%) died) [7], [8], [9], [10], [11, 13], [14], [15], [16], [17, 20]. In all such studies, non-survivors displayed higher levels of blood lactate compared with survivors (Table 3).

Table 3:

Lactate levels in coronavirus disease 2019 (COVID-19) survivors vs. non-survivors.

Study ID Country Type of study Sample size Sex, M/F Age, years, mean Lactate value (mmol/L) (mean) p-Value Endpoint
Survivors Non-survivors
Zhang et al. [7] Wuhan Retrospective 20 11/9 71 ± 8 2.40 ± 0.64 6.47 ± 5.35 0.001 Mortality
Zhao et al. [8] Wuhan Retrospective 539 255/284 58 (43–69) 1.90 (1.43–2.38) 2.40 (1.9–3.65) <0.001 Mortality
Vassiliou et al. [9] Greece Retrospective 42 33/12 64 ± 10 1.4 (1.0–1.8) 2.0 (1.4–2.3) 0.0066 Mortality
Li et al. [11] China Retrospective 25 20/5 60 (49–69) 2.12 (1.63–2.59) 3.93 (2.28–7.52) 0.014 Mortality
Oliveira et al. [12] Portugal Retrospective 364 164/182 81 ± 9 1.54 ± 0.82 2.13 ± 1.89 0.000 Mortality
Sarfaraz et al. [13] Pakistan Prospective 170 133/37 >18 1.3 (1.1–2.0) 2.3 (1.8–3.3) NR Mortality
Birben et al. [14] Turkey NR 388 220/168 54–87 1.68 (1.25–2.21) 2.15 (1.52–3.09) 0.000 Mortality
Alharthy et al. [15] Saudi Arabia Retrospective 352 307/45 51 ± 13 1.61 ± 0.33 2.13 ± 0.34 0.0001 Mortality
Kalabin et al. [16] USA Retrospective 184 111/73 65 ± 15 2.12 ± 1.46 3.33 ± 3.85 0.1 Mortality
Benedetti et al. [17] Italy Observational trial 21 15/6 71 (54–85) 1.1 1.7 0.168 Mortality
Wendel Garcia et al. [20] Europe Prospective 639 447/192 63 1.1 (0.8–1.5) 1.3 (1.0–1.8) 0.005 Mortality

Blood lactate in COVID-19 and non-COVID-19 patients with pneumonia or ARDS

A total number of three studies (150 patients) measured blood lactate levels in COVID-19 pneumonia or ARDS, which were then compared with those measured in non-COVID-19 pneumonia or ARDS of different aetiologies [21], [22], [23]. Notably, blood lactate values were consistently found to be lower in patients with COVID-19 than in those without (Table 4).

Table 4:

Lactate levels in patients with pneumonia and/or acute respiratory distress syndrome (ARDS), with or without coronavirus disease 2019 (COVID-19).

Study ID Country Type of study COVID-19 patients with pneumonia or ARDS Non-COVID-19 patients with pneumonia or ARDS
Sample size Age, years, mean Sex, M/F Lactate value, mmol/L, median Sample size Age, mean Sex, M/F Lactate value, mmol/L, median
Hoechter et al. [21] Germany Retrospective 22 64 (52–70) 19/3 1.1 (1.0–1.4) 14 49 (36–57) 9/5 2.1 (1.1–7.1)
Shi et al. [22] France, Italy Observational 60 64 (54–72) 46/14 1.6 (1.3–2.1) 60 62 (55–73) 34/26 2.2 (1.2–3.5)
Arina et al. [23] London Retrospective 68 62 (53–69) 46/22 5 (7%) patients had lactate >2 mmol/L and concurrent vasopressor use 87 64 (52–75) 64/23 42 (48%) patients had lactate >2 mmol/L and concurrent vasopressor use
  1. ARDS, acute respiratory distress syndrome.

Discussion

Lactate is the most important end product of anaerobic metabolism. Oxygen deprivation of tissue typically leads to lactate hyper-production, as pyruvate can no longer be oxidized in the Krebs cycle due to oxygen deficiency, and is thus converted to lactate [24]. Hyperlactatemia can emerge from several different causes, including tissue hypoxia in sepsis. However, it is important to note that the concentration of this biomarker should not be considered a direct measure of tissue perfusion [25]. Additionally, hyperlactatemia can be induced by medications such as metformin, propofol, and acetaminophen [26], [27], [28]. Predisposing factors to lactic acidosis with metformin are conditions that can be very commonly seen among hospitalized patients with COVID-19 (e.g. hypoperfusion or hypoxemia, such as acute or renal impairment, acute heart failure, acute pulmonary decompensation, and sepsis).

The Surviving Sepsis Campaign guidelines recommend monitoring blood lactate in patients with sepsis or septic shock, guiding resuscitation to decrease serum lactate in patients with elevated lactate level [29]. Accordingly, early lactate clearance-directed therapy is associated with lower mortality [30], thus providing some insights on whether blood lactate monitoring may be helpful in patients with COVID-19.

Patients with severe COVID-19 illness frequently develop interstitial (often bilateral) pneumonia, which may then progress into ARDS or, even worse, with development of a systemic disease, target organ injury, MOF and death in the most severe cases [31]. Currently, COVID-19 treatment guidelines suggest that patients with COVID-19 who require fluid resuscitation should be treated identical to those with septic shock [32], though such indication has not been directly related to blood lactate values.

The results of our systematic literature review unsurprisingly demonstrate that COVID-19 patients with worse outcomes often have higher blood lactate values than those with better outcomes early in disease course (Tables 13). However, careful analysis of the included studies reveals a more complex and variable biochemical picture. Interestingly, in the study by Velavan et al. [10], who measured blood lactate concentration in COVID-19 hospitalized patients and in outpatients in home quarantine after receiving a diagnosis of SARS-CoV-2 infection, reported that blood levels were significantly lower in ambulatory than in hospitalized patients (Table 2). It is important to underpin that most COVID-19 patients in the studies included in our analysis did not have baseline hyperlactatemia and that substantially elevated blood lactate values were often absent in many COVID-19 patients who developed unfavourable clinical outcomes (Tables 13). This suggests that the pathogenesis of severe COVID-19 illness is multifactorial and in part independent from severe ischemia and hyperlactatemia. This hypothesis is confirmed by evidence that patients with COVID-19 pneumonia or ARDS present with lower blood lactate values compared to those with non-COVID-19 pneumonia or ARDS of different aetiologies (Table 4). It could hence be concluded that although an increased blood lactate value may be frequent in COVID-19 patients with unfavourable clinical progression, we should not expect to find the same values that are typically observed in severe pneumonia and/or sepsis (i.e., constantly >2–3 mmol/L). In keeping with this conclusion, Vassiliou et al. [9] measured blood lactate at ICU admission and then every day until day 14. Although these authors found that the time course of blood lactate values mirrored organ dysfunction, frank hyperlactatemia (i.e., >2 mmol/L) was prevalently found only before death, but still only present in less than half (i.e., 45%) of all patients who died with SARS-CoV-2 infection. Further important evidence comes from the study of Lardaro et al. [33], who retrospectively evaluated 542 COVID-19 patients with bacterial co-infection. In these patients, despite the fact that bacteremia was significantly associated with elevated blood lactate values, the clinical outcomes did not significantly differ between patients with and without bacteremia.

In conclusion, the results of our systematic literature review suggest that monitoring blood lactate in patients with SARS-CoV-2 infection upon admission and throughout hospitalization (especially in critical patients and/or those needing mechanical ventilation or intensive care) may be a useful tool for early prediction of higher risk of unfavourable disease progression. Nonetheless, therapeutic decisions based on using a conventional hyperlactatemia cut-off value (i.e., 2.0 or even 3.0 mmol/L) upon first evaluation may be inappropriate in patients with SARS-CoV-2 infection.


Corresponding author: Prof. Giuseppe Lippi, Department of Neurosciences, Section of Clinical Biochemistry, Biomedicine and Movement Sciences, P.le L.A Scuro, 10, 37134 Verona, Italy, Phone: +39 045 8124512, Fax: +0458124514, E-mail:
Giovanni Carpenè, Diletta Onorato and Riccardo Nocini contributed equally to this work.
  1. Research funding: None declared.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: Not applicable.

References

1. Lippi, G, Sanchis-Gomar, F, Henry, BM. COVID-19: unravelling the clinical progression of nature’s virtually perfect biological weapon. Ann Transl Med 2020;8:693. https://doi.org/10.21037/atm-20-3989.Search in Google Scholar PubMed PubMed Central

2. Broder, G, Weil, MH. Excess lactate: an index of reversibility of shock in human patients. Science 1964;143:1457–9. https://doi.org/10.1126/science.143.3613.1457.Search in Google Scholar PubMed

3. Gattinoni, L, Vasques, F, Camporota, L, Meessen, J, Romitti, F, Pasticci, I, et al.. Understanding lactatemia in human sepsis. Potential impact for early management. Am J Respir Crit Care Med 2019;200:582–9. https://doi.org/10.1164/rccm.201812-2342OC.Search in Google Scholar PubMed

4. Lippi, G, Sanchis-Gomar, F, Favaloro, EJ, Lavie, CJ, Henry, BM. Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc 2021;96:203–17. https://doi.org/10.1016/j.mayocp.2020.10.031.Search in Google Scholar PubMed PubMed Central

5. Bruno, RR, Wernly, B, Flaatten, H, Fjølner, J, Artigas, A, Bollen Pinto, B, et al.. Lactate is associated with mortality in very old intensive care patients suffering from COVID-19: results from an international observational study of 2860 patients. Ann Intensive Care 2021;11:128. https://doi.org/10.1186/s13613-021-00911-8.Search in Google Scholar PubMed PubMed Central

6. Hokenek, NM, Rohat, AK. Prognostic value of blood gas lactate levels among COVID-19 patients. J Clin Med Kaz 2021;18:87–90.10.23950/jcmk/11130Search in Google Scholar

7. Zhang, L, Li, J, Zhou, M, Chen, Z. Summary of 20 tracheal intubation by anesthesiologists for patients with severe COVID-19 pneumonia: retrospective case series. J Anesth 2020;34:599–606. https://doi.org/10.1007/s00540-020-02778-8.Search in Google Scholar PubMed PubMed Central

8. Zhao, Y, Nie, HX, Hu, K, Wu, XJ, Zhang, YT, Wang, MM, et al.. Abnormal immunity of non-survivors with COVID-19: predictors for mortality. Infect Dis Poverty 2020;9:108. https://doi.org/10.1186/s40249-020-00723-1.Search in Google Scholar PubMed PubMed Central

9. Vassiliou, AG, Jahaj, E, Ilias, I, Markaki, V, Malachias, S, Vrettou, C, et al.. Lactate kinetics reflect organ dysfunction and are associated with adverse outcomes in intensive care unit patients with COVID-19 pneumonia: preliminary results from a Greek single-centre study. Metabolites 2020;10:386. https://doi.org/10.3390/metabo10100386.Search in Google Scholar PubMed PubMed Central

10. Velavan, TP, Kieu Linh, LT, Kreidenweiss, A, Gabor, J, Krishna, S, Kremsner, PG. Longitudinal monitoring of lactate in hospitalized and ambulatory COVID-19 patients. Am J Trop Med Hyg 2021;104:1041–4. https://doi.org/10.4269/ajtmh.20-1282.Search in Google Scholar PubMed PubMed Central

11. Li, R, Hu, S, Chen, P, Jiang, J, Cui, G, Wang, DW. Saving critically ill COVID-19 patients with mechanical circulatory support. Ann Transl Med 2021;9:1221. https://doi.org/10.21037/atm-20-5169.Search in Google Scholar PubMed PubMed Central

12. Oliveira, J, Gameiro, J, Bernardo, J, Marques, F, Costa, C, Branco, C, et al.. Impact of chronic RAAS use in elderly COVID-19 patients: a retrospective analysis. J Clin Med 2021;10:3147. https://doi.org/10.3390/jcm10143147.Search in Google Scholar PubMed PubMed Central

13. Sarfaraz, S, Shaikh, Q, Saleem, SG, Rahim, A, Herekar, FF, Junejo, S, et al.. Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan. PLoS One 2021;16:e0251754. https://doi.org/10.1371/journal.pone.0251754.Search in Google Scholar PubMed PubMed Central

14. Birben, B, Birben, OD, Akın, T, Akkurt, G, Surel, AA, Yakısık, E, et al.. Efficacy of the delta neutrophil index in predicting 30-day mortality in COVID-19 patients requiring intensive care. Int J Clin Pract 2021;75:e13970. https://doi.org/10.1111/ijcp.13970.Search in Google Scholar PubMed PubMed Central

15. Alharthy, A, Aletreby, W, Faqihi, F, Balhamar, A, Alaklobi, F, Alanezi, K, et al.. Clinical characteristics and predictors of 28-day mortality in 352 critically ill patients with COVID-19: a retrospective study. J Epidemiol Glob Health 2021;11:98–104. https://doi.org/10.2991/jegh.k.200928.001.Search in Google Scholar PubMed PubMed Central

16. Kalabin, A, Mani, VRK, Valdivieso, SC, Donaldson, B. Role of neutrophil-to-lymphocyte, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios as predictors of disease severity in COVID-19 patients. Infez Med 2021;29:46–53.Search in Google Scholar

17. Benedetti, I, Spinelli, D, Callegari, T, Bonometti, R, Molinaro, E, Novara, E, et al.. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: the experience of a single, Italian Center. Eur Rev Med Pharmacol Sci 2021;25:1743–51. https://doi.org/10.26355/eurrev_202102_24885.Search in Google Scholar PubMed

18. Chen, SL, Feng, HY, Xu, H, Huang, SS, Sun, JF, Zhou, L, et al.. Patterns of deterioration in moderate patients with COVID-19 from Jan 2020 to mar 2020: a multi-center, retrospective cohort study in China. Front Med (Lausanne) 2020;7:567296. https://doi.org/10.3389/fmed.2020.567296.Search in Google Scholar PubMed PubMed Central

19. Yang, PH, Ding, YB, Xu, Z, Pu, R, Li, P, Yan, J, et al.. Increased circulating level of interleukin-6 and CD8+ T cell exhaustion are associated with progression of COVID-19. Infect Dis Poverty 2020;9:161. https://doi.org/10.1186/s40249-020-00780-6.Search in Google Scholar PubMed PubMed Central

20. Wendel Garcia, PD, Fumeaux, T, Guerci, P, Heuberger, DM, Montomoli, J, Roche-Campo, F, et al.. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine 2020;25:100449. https://doi.org/10.1016/j.eclinm.2020.100449.Search in Google Scholar PubMed PubMed Central

21. Hoechter, DJ, Becker-Pennrich, A, Langrehr, J, Bruegel, M, Zwissler, B, Schaefer, S, et al.. Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients. Thromb Res 2020;196:186–92. https://doi.org/10.1016/j.thromres.2020.08.030.Search in Google Scholar PubMed PubMed Central

22. Shi, R, Lai, C, Teboul, JL, Dres, M, Moretto, F, De Vita, N, et al.. COVID-19 ARDS is characterized by higher extravascular lung water than non-COVID-19 ARDS: the PiCCOVID study. Crit Care 2021;25:186. https://doi.org/10.1186/s13054-021-03594-6.Search in Google Scholar PubMed PubMed Central

23. Arina, P, Moro, V, Baso, B, Baxter-Derrington, C, Singer, M. Sepsis in severe COVID-19 is rarely septic shock: a retrospective single-centre cohort study. Br J Anaesth 2021;127:e182–5. https://doi.org/10.1016/j.bja.2021.08.007.Search in Google Scholar PubMed PubMed Central

24. Brooks, GA. Lactate as a fulcrum of metabolism. Redox Biol 2020;35:101454. https://doi.org/10.1016/j.redox.2020.101454.Search in Google Scholar PubMed PubMed Central

25. Levy, B. Lactate and shock state: the metabolic view. Curr Opin Crit Care 2006;12:315–21. https://doi.org/10.1097/01.ccx.0000235208.77450.15.Search in Google Scholar PubMed

26. Lucchetta, V, Bonvicini, D, Ballin, A, Tiberio, I. Propofol infusion syndrome in severe COVID-19. Br J Anaesth 2020;125:e441–2. https://doi.org/10.1016/j.bja.2020.08.020.Search in Google Scholar PubMed PubMed Central

27. Kow, CS, Hasan, SS. Metformin use amid coronavirus disease 2019 pandemic. J Med Virol 2020;92:2401–2. https://doi.org/10.1002/jmv.26090.Search in Google Scholar PubMed PubMed Central

28. Rizk, JG, Forthal, DN, Kalantar-Zadeh, K, Mehra, MR, Lavie, CJ, Rizk, Y, et al.. Expanded access programs, compassionate drug use, and emergency use authorizations during the COVID-19 pandemic. Drug Discov Today 2021;26:593–603. https://doi.org/10.1016/j.drudis.2020.11.025.Search in Google Scholar PubMed PubMed Central

29. Evans, L, Rhodes, A, Alhazzani, W, Antonelli, M, Coopersmith, CM, French, C, et al.. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 2021 Oct 2. https://doi.org/10.1007/s00134-021-06506-y [Epub ahead of print].Search in Google Scholar PubMed PubMed Central

30. Pan, J, Peng, M, Liao, C, Hu, X, Wang, A, Li, X. Relative efficacy and safety of early lactate clearance-guided therapy resuscitation in patients with sepsis: a meta-analysis. Medicine (Baltimore) 2019;98:e14453. https://doi.org/10.1097/md.0000000000014453.Search in Google Scholar

31. Lippi, G, Sanchis-Gomar, F, Henry, BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med 2020;8:497. https://doi.org/10.21037/atm.2020.03.157.Search in Google Scholar PubMed PubMed Central

32. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Bethesda (MD): National Institutes of Health (US); 2021.Search in Google Scholar

33. Lardaro, T, Wang, AZ, Bucca, A, Croft, A, Glober, N, Holt, DB, et al.. Characteristics of COVID-19 patients with bacterial coinfection admitted to the hospital from the emergency department in a large regional healthcare system. J Med Virol 2021;93:2883–9. https://doi.org/10.1002/jmv.26795.Search in Google Scholar PubMed PubMed Central

Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2021-1115).

Received: 2021-10-17
Accepted: 2021-11-12
Published Online: 2021-12-02
Published in Print: 2022-02-23

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2021-1115/html
Scroll to top button